These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 39044638)
1. Stability of Neutralizing Antibody of PastoCoAd Vaccine Candidates against a Variant of Concern of SARS-CoV-2 in Animal Models. Panahi M; Teimoori A; Esmaeili S; Aminianfar H; Milani A; Hosseini SY; Esmaeili P; Biglari A; Baesi K Iran Biomed J; 2024 Jul; 28(4):214-20. PubMed ID: 39044638 [TBL] [Abstract][Full Text] [Related]
2. Potency, toxicity and protection evaluation of PastoCoAd candidate vaccines: Novel preclinical mix and match rAd5 S, rAd5 RBD-N and SOBERANA dimeric-RBD protein. Hassan PM; Ali T; Saber E; Asghar A; Delaram D; Mostafa SV; Maryam S; Maryam K; Talieh S; Ali KM; Mohammad P; Fereidoon K; Anahita B; Yury VB; Dagmar GR; Vicente VB; Alireza B; Kazem B Vaccine; 2022 May; 40(20):2856-2868. PubMed ID: 35393148 [TBL] [Abstract][Full Text] [Related]
3. MVA-based vaccine candidates expressing SARS-CoV-2 prefusion-stabilized spike proteins of the Wuhan, Beta or Omicron BA.1 variants protect transgenic K18-hACE2 mice against Omicron infection and elicit robust and broad specific humoral and cellular immune responses. Pérez P; Astorgano D; Albericio G; Flores S; Sánchez-Corzo C; Noriega MA; Sánchez-Cordón PJ; Labiod N; Delgado R; Casasnovas JM; Esteban M; García-Arriaza J Front Immunol; 2024; 15():1420304. PubMed ID: 39267752 [TBL] [Abstract][Full Text] [Related]
4. A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection. Shi J; Zheng J; Tai W; Verma AK; Zhang X; Geng Q; Wang G; Guan X; Malisheni MM; Odle AE; Zhang W; Li F; Perlman S; Du L J Virol; 2022 Sep; 96(17):e0011822. PubMed ID: 35972290 [TBL] [Abstract][Full Text] [Related]
5. A Methyltransferase-Defective Vesicular Stomatitis Virus-Based SARS-CoV-2 Vaccine Candidate Provides Complete Protection against SARS-CoV-2 Infection in Hamsters. Lu M; Zhang Y; Dravid P; Li A; Zeng C; Kc M; Trivedi S; Sharma H; Chaiwatpongsakorn S; Zani A; Kenney A; Cai C; Ye C; Liang X; Qiu J; Martinez-Sobrido L; Yount JS; Boyaka PN; Liu SL; Peeples ME; Kapoor A; Li J J Virol; 2021 Sep; 95(20):e0059221. PubMed ID: 34379509 [TBL] [Abstract][Full Text] [Related]
6. Immunogenicity of an adenovirus-vectored bivalent vaccine against wild type SARS-CoV-2 and Omicron variants in a murine model. Ji Y; Sui X; Miao W; Wang C; Wang Q; Duan Z; Wei B; Wu D; Wei M; Shao J; Zheng X; Zhu T Vaccine; 2024 Feb; 42(6):1292-1299. PubMed ID: 38296705 [TBL] [Abstract][Full Text] [Related]
7. Intranasal HD-Ad-FS vaccine induces systemic and airway mucosal immunities against SARS-CoV-2 and systemic immunity against SARS-CoV-2 variants in mice and hamsters. Zhou P; Watt J; Mai J; Cao H; Li Z; Chen Z; Duan R; Quan Y; Gingras AC; Rini JM; Hu J; Liu J Front Immunol; 2024; 15():1430928. PubMed ID: 39281669 [TBL] [Abstract][Full Text] [Related]
8. Design of the conserved epitope peptide of SARS-CoV-2 spike protein as the broad-spectrum COVID-19 vaccine. Chang TY; Li CJ; Chao TL; Chang SY; Chang SC Appl Microbiol Biotechnol; 2024 Oct; 108(1):486. PubMed ID: 39412657 [TBL] [Abstract][Full Text] [Related]
9. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. Weisblum Y; Schmidt F; Zhang F; DaSilva J; Poston D; Lorenzi JC; Muecksch F; Rutkowska M; Hoffmann HH; Michailidis E; Gaebler C; Agudelo M; Cho A; Wang Z; Gazumyan A; Cipolla M; Luchsinger L; Hillyer CD; Caskey M; Robbiani DF; Rice CM; Nussenzweig MC; Hatziioannou T; Bieniasz PD Elife; 2020 Oct; 9():. PubMed ID: 33112236 [TBL] [Abstract][Full Text] [Related]
10. Deciphering the Role of Humoral and Cellular Immune Responses in Different COVID-19 Vaccines-A Comparison of Vaccine Candidate Genes in Roborovski Dwarf Hamsters. Trimpert J; Herwig S; Stein J; Vladimirova D; Adler JM; Abdelgawad A; Firsching TC; Thoma T; Sehouli J; Osterrieder K; Gruber AD; Sawitzki B; Sander LE; Cichon G Viruses; 2021 Nov; 13(11):. PubMed ID: 34835096 [TBL] [Abstract][Full Text] [Related]
11. Co-administration of recombinant BCG and SARS-CoV-2 proteins leads to robust antiviral immunity. Ramírez MA; Loaiza RA; Martínez-Balboa Y; Bruneau N; Ramírez E; González PA; Bueno SM; Kalergis AM Vaccine; 2024 Oct; 42(23):126203. PubMed ID: 39178767 [TBL] [Abstract][Full Text] [Related]
12. Comparative immunogenicity of monovalent and bivalent adenovirus vaccines carrying spikes of early and late SARS-CoV-2 variants. Li H; Yang C; Yin L; Liu W; Zhang Z; Liu B; Sun X; Liu W; Lin Z; Liu Z; He P; Feng Y; Wang C; Wang W; Guan S; Wang Q; Chen L; Li P Emerg Microbes Infect; 2024 Dec; 13(1):2387447. PubMed ID: 39082740 [TBL] [Abstract][Full Text] [Related]
13. A chimeric mRNA vaccine of S-RBD with HA conferring broad protection against influenza and COVID-19 variants. Hao T; Li Y; Liu P; Wang X; Xu K; Lei W; Li Y; Zhang R; Li X; Zhao X; Xu K; Lu X; Bi Y; Song H; Wu G; Zhu B; Gao GF PLoS Pathog; 2024 Sep; 20(9):e1012508. PubMed ID: 39303003 [TBL] [Abstract][Full Text] [Related]
14. Construction and immunogenicity of SARS-CoV-2 virus-like particle expressed by recombinant baculovirus BacMam. Nguyen HT; Falzarano D; Gerdts V; Liu Q Microbiol Spectr; 2024 Aug; 12(8):e0095924. PubMed ID: 38916311 [TBL] [Abstract][Full Text] [Related]
15. A measles-vectored vaccine candidate expressing prefusion-stabilized SARS-CoV-2 spike protein brought to phase I/II clinical trials: candidate selection in a preclinical murine model. Brunet J; Choucha Z; Gransagne M; Tabbal H; Ku M-W; Buchrieser J; Fernandes P; Batalie D; Lopez J; Ma L; Dufour E; Simon E; Hardy D; Petres S; Guinet F; Strick-Marchand H; Monot M; Charneau P; Majlessi L; Duprex WP; Gerke C; Martin A; Escriou N J Virol; 2024 May; 98(5):e0169323. PubMed ID: 38563763 [TBL] [Abstract][Full Text] [Related]
16. Antibody cocktail effective against variants of SARS-CoV-2. Liang KH; Chiang PY; Ko SH; Chou YC; Lu RM; Lin HT; Chen WY; Lin YL; Tao MH; Jan JT; Wu HC J Biomed Sci; 2021 Nov; 28(1):80. PubMed ID: 34814920 [TBL] [Abstract][Full Text] [Related]
17. Three in one: An effective and universal vaccine expressing heterologous tandem RBD trimer by rabies virus vector protects mice against SARS-CoV-2. Huang J; Wang W; Li H; Bai Y; Song Y; Jiao C; Jin H; Huang P; Zhang H; Xia X; Yan F; Li Y; Wang H Antiviral Res; 2024 Jul; 227():105905. PubMed ID: 38740191 [TBL] [Abstract][Full Text] [Related]
18. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain. Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438 [TBL] [Abstract][Full Text] [Related]
19. A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants. Zhang J; Han ZB; Liang Y; Zhang XF; Jin YQ; Du LF; Shao S; Wang H; Hou JW; Xu K; Lei W; Lei ZH; Liu ZM; Zhang J; Hou YN; Liu N; Shen FJ; Wu JJ; Zheng X; Li XY; Li X; Huang WJ; Wu GZ; Su JG; Li QM Elife; 2022 Aug; 11():. PubMed ID: 36004719 [TBL] [Abstract][Full Text] [Related]
20. Elicitation of Broadly Neutralizing Antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 Variants by Three Prototype Strain-Derived Recombinant Protein Vaccines. Yang Y; Zang J; Xu S; Zhang X; Yuan S; Wang H; Lavillette D; Zhang C; Huang Z Viruses; 2021 Jul; 13(8):. PubMed ID: 34452287 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]